NURS 6675 / NRNP-6675 PMHNP Care Across the Lifespan
II Midterm Exam Prep Document | 2026/2027 Edition | 150
Verified Questions - 120 Questions with Answers
NURS 6675 / NRNP-6675 PMHNP Care Across the Lifespan II Midterm Exam 2026-120 QUESTIONS AND
ANSWERS ALREADY GRADED A+. 100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive midterm exam preparation document for NURS 6675 / NRNP-6675 (PMHNP
Care Across the Lifespan II) contains 150 verified practice questions with correct answers and detailed
rationales. Designed for the 2026/2027 academic year, it aligns with the latest PMHNP competencies
and evidence-based guidelines. Each question reflects the depth and breadth of the midterm
curriculum, ensuring thorough readiness. The document is an essential resource for psychiatric mental
health nurse practitioner students aiming to excel in their midterm examination.
Key Features:
Foundations of Psychiatric Mental Health Nursing Across the Lifespan
Neurobiology and Psychopharmacology Across the Lifespan
Psychiatric Assessment and Diagnostic Reasoning
Mood Disorders: Major Depressive Disorder and Bipolar Disorders
Anxiety Disorders: Generalized Anxiety, Panic, Social Anxiety, and Separation Anxiety
Trauma- and Stressor-Related Disorders: PTSD and Acute Stress Disorder
Schizophrenia Spectrum and Other Psychotic Disorders
Personality Disorders: Cluster A, B, and C
Substance-Related and Addictive Disorders: Assessment and Management
Neurodevelopmental Disorders: ADHD, Autism Spectrum, and Intellectual Disability
Eating Disorders: Anorexia, Bulimia, and Binge-Eating Disorder
Sleep-Wake Disorders: Insomnia, Hypersomnia, and Circadian Rhythm Disorders
Somatic Symptom and Related Disorders
Ethical, Legal, and Professional Issues in PMHNP Practice
Integrated Care and Interprofessional Collaboration
Cultural Competence and Health Disparities in Mental Health Care
Updates for 2026:
- Updated to reflect the 2026/2027 PMHNP curriculum and latest AANP/ANCC exam blueprints
- Incorporated new DSM-5-TR diagnostic criteria and updates
- Revised rationales to align with current evidence-based practice guidelines
- Added questions on telehealth and digital mental health interventions
- Enhanced coverage of psychopharmacology with new FDA-approved medications and black box warnings
Abstract:
This exam preparation document is meticulously crafted for graduate nursing students enrolled in NURS 6675 /
NRNP-6675, focusing on psychiatric mental health care across the lifespan. It comprises 150 practice questions
that mirror the format and complexity of the midterm examination, with verified answers and comprehensive
rationales. The content spans the full spectrum of PMHNP practice, including neurobiology, pharmacotherapy,
psychotherapy, and management of psychiatric disorders from childhood through older adulthood. Emphasis is
placed on clinical reasoning, differential diagnosis, and evidence-based interventions. The document also
addresses ethical, legal, and cultural considerations essential for advanced practice nursing. By engaging with
these questions, students will reinforce their knowledge, identify areas for further study, and build confidence for
Page 1
,exam success. This resource is an invaluable tool for achieving a high score and demonstrating clinical
competence.
Keywords:
PMHNP, NURS 6675, NRNP-6675, Midterm Exam, Psychiatric Mental Health, Lifespan, Practice Questions,
Verified Answers
Answer Format:
Each question is presented in multiple-choice format with four options. The correct answer is clearly indicated,
followed by a detailed rationale explaining why it is correct and why the distractors are incorrect. Rationales
include relevant diagnostic criteria, pharmacological mechanisms, and clinical guidelines to enhance learning.
Compliance Checklist:
All questions align with the latest PMHNP certification exam blueprints
Content reflects DSM-5-TR diagnostic criteria and updates
Pharmacological questions reference current FDA-approved medications and safety guidelines
Rationales cite evidence-based practice and reputable sources
Questions cover all age groups from pediatric to geriatric populations
Includes ethical and legal considerations in psychiatric care
Content Area Overview:
Content Area Questions Key Topics Weight
Foundations of PMHNP Practice 1-10 Role of PMHNP, therapeutic relationship, 7%
recovery model, evidence-based practice
Neurobiology and 11-25 Neurotransmitters, receptor binding, 10%
Psychopharmacology pharmacokinetics, pharmacodynamics,
psychotropic drug classes
Psychiatric Assessment and 26-35 Mental status exam, diagnostic interviews, 7%
Diagnosis rating scales, differential diagnosis
Mood Disorders 36-50 Major depressive disorder, bipolar I/II, 10%
cyclothymia, treatment algorithms, suicide
risk
Anxiety Disorders 51-65 GAD, panic disorder, social anxiety, 10%
separation anxiety, phobias, treatment
options
Trauma- and Stressor-Related 66-75 PTSD, acute stress disorder, adjustment 7%
Disorders disorders, trauma-informed care
Schizophrenia Spectrum and 76-90 Schizophrenia, schizoaffective disorder, 10%
Psychotic Disorders delusional disorder, antipsychotic
management
Personality Disorders 91-100 Cluster A, B, C personality disorders, 7%
dialectical behavior therapy, management
strategies
Substance-Related and Addictive 101-110 Alcohol, opioids, stimulants, cannabis, 7%
Disorders withdrawal management, MAT
Neurodevelopmental Disorders 111-120 ADHD, autism spectrum disorder, 7%
intellectual disability, behavioral
interventions
Page 2
,Eating Disorders 121-130 Anorexia nervosa, bulimia nervosa, 7%
binge-eating disorder, medical
complications, treatment
Sleep-Wake Disorders 131-140 Insomnia, obstructive sleep apnea, 7%
narcolepsy, circadian rhythm disorders,
CBT-I
Somatic Symptom and Related 141-145 Somatic symptom disorder, illness anxiety 3%
Disorders disorder, conversion disorder, factitious
disorder
Ethical, Legal, and Professional 146-150 Informed consent, confidentiality, 3%
Issues mandatory reporting, boundary issues, scope
of practice
Page 3
, Q1. In the context of treatment-resistant depression, which neurobiological
mechanism best explains the rapid antidepressant effect of a single subanesthetic dose
of ketamine?
A. Antagonism at the N-methyl-D-aspartate (NMDA) receptor leading to increased
glutamate release and activation of -amino-3-hydroxy-5-methyl-4-isoxazolepropionic
acid (AMPA) receptors
B. Inhibition of monoamine oxidase A, increasing synaptic concentrations of serotonin,
norepinephrine, and dopamine
C. Blockade of the serotonin reuptake transporter, leading to downregulation of
5-HT1A autoreceptors over weeks
D. Agonism at the gamma-aminobutyric acid (GABA) type A receptor, enhancing
inhibitory neurotransmission
Correct Answer: A. Antagonism at the N-methyl-D-aspartate (NMDA) receptor
leading to increased glutamate release and activation of
-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors
Rationale: Ketamine is an NMDA receptor antagonist. By blocking NMDA receptors on
GABAergic interneurons, it disinhibits glutamate release, which then stimulates AMPA
receptors, leading to a cascade that enhances synaptic plasticity and rapidly increases
brain-derived neurotrophic factor (BDNF). This mechanism underlies its rapid
antidepressant effects, unlike traditional antidepressants that take weeks.
Why Wrong:
B - MAO inhibitors work by inhibiting monoamine oxidase, but this mechanism does
not explain ketamine's rapid onset.
C - SSRIs block serotonin reuptake and take weeks to produce downregulation of
autoreceptors, not rapid effects.
D - GABA-A agonism is associated with anxiolytic and sedative effects, not rapid
antidepressant action.
Reference: Stahl, S. M. (2021). Stahl's Essential Psychopharmacology, 5th Ed., Ch. 3, 8.
Q2. An individual with bipolar I disorder is currently experiencing a manic episode.
Which combination of pharmacologic agents is most appropriate for acute
management while minimizing the risk of inducing a depressive switch?
A. Lithium and olanzapine
B. Valproate and aripiprazole
C. Lamotrigine and fluoxetine
D. Quetiapine and venlafaxine
Correct Answer: B. Valproate and aripiprazole
Rationale: Valproate (mood stabilizer) and aripiprazole (atypical antipsychotic) are both
effective for acute mania and have a lower risk of inducing depression compared to some
Page 4
II Midterm Exam Prep Document | 2026/2027 Edition | 150
Verified Questions - 120 Questions with Answers
NURS 6675 / NRNP-6675 PMHNP Care Across the Lifespan II Midterm Exam 2026-120 QUESTIONS AND
ANSWERS ALREADY GRADED A+. 100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive midterm exam preparation document for NURS 6675 / NRNP-6675 (PMHNP
Care Across the Lifespan II) contains 150 verified practice questions with correct answers and detailed
rationales. Designed for the 2026/2027 academic year, it aligns with the latest PMHNP competencies
and evidence-based guidelines. Each question reflects the depth and breadth of the midterm
curriculum, ensuring thorough readiness. The document is an essential resource for psychiatric mental
health nurse practitioner students aiming to excel in their midterm examination.
Key Features:
Foundations of Psychiatric Mental Health Nursing Across the Lifespan
Neurobiology and Psychopharmacology Across the Lifespan
Psychiatric Assessment and Diagnostic Reasoning
Mood Disorders: Major Depressive Disorder and Bipolar Disorders
Anxiety Disorders: Generalized Anxiety, Panic, Social Anxiety, and Separation Anxiety
Trauma- and Stressor-Related Disorders: PTSD and Acute Stress Disorder
Schizophrenia Spectrum and Other Psychotic Disorders
Personality Disorders: Cluster A, B, and C
Substance-Related and Addictive Disorders: Assessment and Management
Neurodevelopmental Disorders: ADHD, Autism Spectrum, and Intellectual Disability
Eating Disorders: Anorexia, Bulimia, and Binge-Eating Disorder
Sleep-Wake Disorders: Insomnia, Hypersomnia, and Circadian Rhythm Disorders
Somatic Symptom and Related Disorders
Ethical, Legal, and Professional Issues in PMHNP Practice
Integrated Care and Interprofessional Collaboration
Cultural Competence and Health Disparities in Mental Health Care
Updates for 2026:
- Updated to reflect the 2026/2027 PMHNP curriculum and latest AANP/ANCC exam blueprints
- Incorporated new DSM-5-TR diagnostic criteria and updates
- Revised rationales to align with current evidence-based practice guidelines
- Added questions on telehealth and digital mental health interventions
- Enhanced coverage of psychopharmacology with new FDA-approved medications and black box warnings
Abstract:
This exam preparation document is meticulously crafted for graduate nursing students enrolled in NURS 6675 /
NRNP-6675, focusing on psychiatric mental health care across the lifespan. It comprises 150 practice questions
that mirror the format and complexity of the midterm examination, with verified answers and comprehensive
rationales. The content spans the full spectrum of PMHNP practice, including neurobiology, pharmacotherapy,
psychotherapy, and management of psychiatric disorders from childhood through older adulthood. Emphasis is
placed on clinical reasoning, differential diagnosis, and evidence-based interventions. The document also
addresses ethical, legal, and cultural considerations essential for advanced practice nursing. By engaging with
these questions, students will reinforce their knowledge, identify areas for further study, and build confidence for
Page 1
,exam success. This resource is an invaluable tool for achieving a high score and demonstrating clinical
competence.
Keywords:
PMHNP, NURS 6675, NRNP-6675, Midterm Exam, Psychiatric Mental Health, Lifespan, Practice Questions,
Verified Answers
Answer Format:
Each question is presented in multiple-choice format with four options. The correct answer is clearly indicated,
followed by a detailed rationale explaining why it is correct and why the distractors are incorrect. Rationales
include relevant diagnostic criteria, pharmacological mechanisms, and clinical guidelines to enhance learning.
Compliance Checklist:
All questions align with the latest PMHNP certification exam blueprints
Content reflects DSM-5-TR diagnostic criteria and updates
Pharmacological questions reference current FDA-approved medications and safety guidelines
Rationales cite evidence-based practice and reputable sources
Questions cover all age groups from pediatric to geriatric populations
Includes ethical and legal considerations in psychiatric care
Content Area Overview:
Content Area Questions Key Topics Weight
Foundations of PMHNP Practice 1-10 Role of PMHNP, therapeutic relationship, 7%
recovery model, evidence-based practice
Neurobiology and 11-25 Neurotransmitters, receptor binding, 10%
Psychopharmacology pharmacokinetics, pharmacodynamics,
psychotropic drug classes
Psychiatric Assessment and 26-35 Mental status exam, diagnostic interviews, 7%
Diagnosis rating scales, differential diagnosis
Mood Disorders 36-50 Major depressive disorder, bipolar I/II, 10%
cyclothymia, treatment algorithms, suicide
risk
Anxiety Disorders 51-65 GAD, panic disorder, social anxiety, 10%
separation anxiety, phobias, treatment
options
Trauma- and Stressor-Related 66-75 PTSD, acute stress disorder, adjustment 7%
Disorders disorders, trauma-informed care
Schizophrenia Spectrum and 76-90 Schizophrenia, schizoaffective disorder, 10%
Psychotic Disorders delusional disorder, antipsychotic
management
Personality Disorders 91-100 Cluster A, B, C personality disorders, 7%
dialectical behavior therapy, management
strategies
Substance-Related and Addictive 101-110 Alcohol, opioids, stimulants, cannabis, 7%
Disorders withdrawal management, MAT
Neurodevelopmental Disorders 111-120 ADHD, autism spectrum disorder, 7%
intellectual disability, behavioral
interventions
Page 2
,Eating Disorders 121-130 Anorexia nervosa, bulimia nervosa, 7%
binge-eating disorder, medical
complications, treatment
Sleep-Wake Disorders 131-140 Insomnia, obstructive sleep apnea, 7%
narcolepsy, circadian rhythm disorders,
CBT-I
Somatic Symptom and Related 141-145 Somatic symptom disorder, illness anxiety 3%
Disorders disorder, conversion disorder, factitious
disorder
Ethical, Legal, and Professional 146-150 Informed consent, confidentiality, 3%
Issues mandatory reporting, boundary issues, scope
of practice
Page 3
, Q1. In the context of treatment-resistant depression, which neurobiological
mechanism best explains the rapid antidepressant effect of a single subanesthetic dose
of ketamine?
A. Antagonism at the N-methyl-D-aspartate (NMDA) receptor leading to increased
glutamate release and activation of -amino-3-hydroxy-5-methyl-4-isoxazolepropionic
acid (AMPA) receptors
B. Inhibition of monoamine oxidase A, increasing synaptic concentrations of serotonin,
norepinephrine, and dopamine
C. Blockade of the serotonin reuptake transporter, leading to downregulation of
5-HT1A autoreceptors over weeks
D. Agonism at the gamma-aminobutyric acid (GABA) type A receptor, enhancing
inhibitory neurotransmission
Correct Answer: A. Antagonism at the N-methyl-D-aspartate (NMDA) receptor
leading to increased glutamate release and activation of
-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors
Rationale: Ketamine is an NMDA receptor antagonist. By blocking NMDA receptors on
GABAergic interneurons, it disinhibits glutamate release, which then stimulates AMPA
receptors, leading to a cascade that enhances synaptic plasticity and rapidly increases
brain-derived neurotrophic factor (BDNF). This mechanism underlies its rapid
antidepressant effects, unlike traditional antidepressants that take weeks.
Why Wrong:
B - MAO inhibitors work by inhibiting monoamine oxidase, but this mechanism does
not explain ketamine's rapid onset.
C - SSRIs block serotonin reuptake and take weeks to produce downregulation of
autoreceptors, not rapid effects.
D - GABA-A agonism is associated with anxiolytic and sedative effects, not rapid
antidepressant action.
Reference: Stahl, S. M. (2021). Stahl's Essential Psychopharmacology, 5th Ed., Ch. 3, 8.
Q2. An individual with bipolar I disorder is currently experiencing a manic episode.
Which combination of pharmacologic agents is most appropriate for acute
management while minimizing the risk of inducing a depressive switch?
A. Lithium and olanzapine
B. Valproate and aripiprazole
C. Lamotrigine and fluoxetine
D. Quetiapine and venlafaxine
Correct Answer: B. Valproate and aripiprazole
Rationale: Valproate (mood stabilizer) and aripiprazole (atypical antipsychotic) are both
effective for acute mania and have a lower risk of inducing depression compared to some
Page 4
